EUVIMEDEUVIMED entdecken
Crossref

METTL3 potentiates osteogenic differentiation of bone marrow mesenchymal stem cells via IGF2BP1 / m6A / RUNX2

Shuzuo Zhou, Gang Zhang, Kun Wang, Zhong Yang, Yinghui Tan

Oral Diseases · 2024-04 · 30 (3) · 1313-1321

DOI: 10.1111/odi.14526 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oral Diseases, online erschienen am 13.03.2023. Verfasst von Shuzuo Zhou und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Stomatology, Xin Qiao Hospital, Chongqing, China. Hauptthemen laut MEDLINE: Cell Differentiation, Core Binding Factor Alpha 1 Subunit, Mesenchymal Stem Cells, Methyltransferases. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Maxillofacial bone defect is a critical obstacle for maxillofacial tumors and periodontal diseases. The osteogenic differentiation of bone marrow mesenchymal stem cells BMSCs is critical for maxillofacial osteogenesis and functional reconstruction. Here, our study focused on the functions and mechanism of N 6 ‐methyladenosine during BMSCs osteogenic differentiation BMSCs. Subject and Methods Biofunctions of BMSCs were detected using ALP activity and alizarin red S staining assays. The molecular interaction within RNA/protein was identified by RNA immunoprecipitation and/or methylation immunoprecipitation.

Results

Results indicated that m 6 A ‘writer’ METTL3 upregulated during the osteogenic differentiation of BMSCs upon osteogenic induction. Functionally, assays' results revealed that METTL3 overexpression promoted the osteogenic differentiation of BMSC, while METTL3 knockdown repressed the osteogenic differentiation. Mechanistically, results revealed that RUNX2 mRNA was a m 6 A‐methylated target by METTL3 at its 3'‐UTR. Moreover, m 6 A reader IGF2BP1 recognized the m 6 A site on RUNX2 mRNA to enhance its stability.

Conclusion

In conclusion, our findings revealed the novel roles of METTL3 in BMSCs osteogenic differentiation via the IGF2BP1/m 6 A/RUNX2 signaling axis of m 6 A‐dependent manner, providing a potential therapeutic target for maxillofacial bone defects treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cell DifferentiationCore Binding Factor Alpha 1 SubunitMesenchymal Stem CellsMethyltransferasesOsteogenesisHumansAdenosineCells, CulturedRNA, MessengerRNA-Binding ProteinsSignal Transduction

Stichwörter der Autor:innen

METTL3N6‐methyladenosineRUNX2bone marrow mesenchymal stem cells

Substanzen

AdenosineCore Binding Factor Alpha 1 SubunitIGF2BP1 protein, humanMethyltransferasesMETTL3 protein, humanN-methyladenosineRNA, MessengerRNA-Binding ProteinsRUNX2 protein, human

Autor:innen und Institutionen

  • Department of Stomatology, Xin Qiao Hospital, Chongqing, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhou, S., Zhang, G., Wang, K., Yang, Z., & Tan, Y. (2024). METTL3 potentiates osteogenic differentiation of bone marrow mesenchymal stem cells via IGF2BP1 / m6A / RUNX2. Oral Diseases, 30(3), 1313-1321. https://doi.org/10.1111/odi.14526

Vancouver

Zhou S, Zhang G, Wang K, Yang Z, Tan Y. METTL3 potentiates osteogenic differentiation of bone marrow mesenchymal stem cells via IGF2BP1 / m6A / RUNX2. Oral Diseases. 2024;30(3):1313-1321. doi:10.1111/odi.14526

BibTeX
@article{Zhou2024,
  author = {Zhou, Shuzuo and Zhang, Gang and Wang, Kun and Yang, Zhong and Tan, Yinghui},
  title = {METTL3 potentiates osteogenic differentiation of bone marrow mesenchymal stem cells via IGF2BP1 / m6A / RUNX2},
  journal = {Oral Diseases},
  year = {2024},
  volume = {30},
  number = {3},
  pages = {1313--1321},
  doi = {10.1111/odi.14526}
}
Kostenlos starten →